Patents by Inventor Shanker Gupta
Shanker Gupta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240059303Abstract: One or more embodiments include techniques for automating vehicle routines. The techniques include receiving a rule that includes one or more deterministic elements and a machine learning element; collecting, during operation of the vehicle, a set of vehicle data based on the machine learning element; training a machine learning model that corresponds to the machine learning element using the set of vehicle data, wherein the machine learning model is used to process the machine learning element during execution of the rule.Type: ApplicationFiled: August 15, 2023Publication date: February 22, 2024Inventors: Harinarayanan Kuruthikadavath KURUSSITHODI, Rajesh BISWAL, Ravi Shanker GUPTA
-
Patent number: 10913709Abstract: Disclosed is a salt prepared from the STAT3 inhibitor known as 2-hydroxy-4-[[2-[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino] benzoic acid and 2-amino-2-(hydroxymethyl)-1,3-propanediol. The salt is soluble in water and stable for extended periods of time. Further provided are pharmaceutical compositions comprising the salt and methods of administering the salt to prevent and treat cancer, such as breast cancer.Type: GrantFiled: April 5, 2018Date of Patent: February 9, 2021Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, GLG Pharma, LLC, MRIGlobalInventors: Robert H. Shoemaker, Michael W. Lovell, Jonathan M. White, Shanker Gupta
-
Publication number: 20200109109Abstract: Disclosed is a salt prepared from the STAT3 inhibitor known as 2-hydroxy-4-[[2-[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino] benzoic acid and 2-amino-2-(hydroxymethyl)-1,3-propanediol. The salt is soluble in water and stable for extended periods of time. Further provided are pharmaceutical compositions comprising the salt and methods of administering the salt to prevent and treat cancer, such as breast cancer.Type: ApplicationFiled: April 5, 2018Publication date: April 9, 2020Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, GLG Pharma, LLC, MRIGlobalInventors: Robert H. Shoemaker, Michael W. Lovell, Jonathan M. White, Shanker Gupta
-
Patent number: 7476692Abstract: The present invention provides stable aqueous solutions consisting essentially of: (a) a sphingolipid; (b) lactic acid; and (c) optionally a stabilizing agent; wherein the solution has a molar ratio of lactic acid to sphingolipid of 1:1 to 10:1. The present invention further provides an emulsion formulation consisting essentially of: (a) lactic acid; (b) a sphingolipid, wherein the sphingolipid is present in an amount of about 0.1 to about 30 mg/ml of emulsion; (b) optionally an isotonic agent; and (c) a phospholipid present in an amount of about 0.2 to about 200 mg/ml of emulsion. Methods of making and using the compositions are also provided.Type: GrantFiled: February 19, 2004Date of Patent: January 13, 2009Assignee: Childrens Hospital Los AngelesInventors: Shanker Gupta, C. Patrick Reynolds, Barry J. Maurer, B. Rao Vishnuvajjala
-
Patent number: 7169819Abstract: A pharmaceutical composition for parenteral delivery, comprising a retinide such as fenretinide in combination with a solvent capable of dispersing or solubilizing the retinide. The solvent comprises an alcohol, such as ethanol, in combination with an alkoxylated castor oil, such as CREMOPHOR® EL, or comprising a retinide, such as fenretinide, in an emulsion composed of a lipoid dispersed in an aqueous phase, a stabilizing amount of a non-ionic surfactant, optionally a solvent, and optionally an isotonic agent. In addition, a method of use in the treatment of hyperproliferative disorders, such as cancers is described.Type: GrantFiled: December 5, 2001Date of Patent: January 30, 2007Assignee: Childrens Hospital Los AngelesInventors: Shanker Gupta, Barry J. Maurer, C. Patrick Reynolds, B. Rao Vishnuvajjala
-
Publication number: 20050282742Abstract: The invention relates to the formulation of pharmaceutical compounds. More particularly, the invention provides stable, pharmaceutically acceptable compositions prepared from boronic acid compounds and methods for preparing the compositions. The invention also provides novel boronate ester compounds. The invention further provides boronic acid anhydride compounds useful in the methods of the invention.Type: ApplicationFiled: July 19, 2005Publication date: December 22, 2005Applicants: Government of the USA, represented by the Secretary,Dept. of Health and Human Services, Millennium Parmaceuticals, Inc.Inventors: Louis Plamondon, Louis Grenier, Julian Adams, Shanker Gupta
-
Publication number: 20050187186Abstract: The present invention provides stable aqueous solutions consisting essentially of: (a) a sphingolipid; (b) lactic acid; and (c) optionally a stabilizing agent; wherein the solution has a molar ratio of lactic acid to sphingolipid of 1:1 to 10:1. The present invention further provides an emulsion formulation consisting essentially of: (a) lactic acid; (b) a sphingolipid, wherein the sphingolipid is present in an amount of about 0.1 to about 30 mg/ml of emulsion; (b) optionally an isotonic agent; and (c) a phospholipid present in an amount of about 0.2 to about 200 mg/ml of emulsion. Methods of making and using the compositions are also provided.Type: ApplicationFiled: February 19, 2004Publication date: August 25, 2005Inventors: Barry Maurer, Shanker Gupta, C. Reynolds, B. Vishnuvajjala
-
Patent number: 6838090Abstract: The present invention provides a drug delivery system comprising a water-insoluble drug, a water-miscible organic solvent for the water-insoluble drug, a surfactant, and water, as well as a process for preparing the same. This invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and such a drug delivery system. In addition, the present invention provides a method of delivering a drug to a host by administering to the host the drug delivery system of the present invention.Type: GrantFiled: June 5, 2003Date of Patent: January 4, 2005Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: S. Esmail Tabibi, Emmanuel I. Ezennia, B. Rao Vishnuvajjala, Shanker Gupta
-
Patent number: 6682758Abstract: The present invention provides a drug delivery system comprising a water-insoluble drug, a water-miscible organic solvent for the water-insoluble drug, a surfactant, and water, as well as a process for preparing the same. This invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and such a drug delivery system. In addition, the present invention provides a method of delivering a drug to a host by administering to the host the drug delivery system of the present invention.Type: GrantFiled: June 21, 2001Date of Patent: January 27, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: S. Esmail Tabibi, Emmanuel I. Ezennia, B. Rao Vishnuvajjala, Shanker Gupta
-
Publication number: 20030211144Abstract: The present invention provides a drug delivery system comprising a water-insoluble drug, a water-miscible organic solvent for the water-insoluble drug, a surfactant, and water, as well as a process for preparing the same. This invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and such a drug delivery system. In addition, the present invention provides a method of delivering a drug to a host by administering to the host the drug delivery system of the present invention.Type: ApplicationFiled: June 5, 2003Publication date: November 13, 2003Applicant: Government of the U.S.A., represented by the Secretary, Department of Health and Human ServicesInventors: S. Esmail Tabibi, Emmanuel I. Ezennia, B. Rao Vishnuvajjala, Shanker Gupta
-
Publication number: 20020183394Abstract: A pharmaceutical composition for parenteral delivery, comprising a retinide such as fenretinide in combination with a solvent capable of dispersing or solubilizing the retinide. The solvent comprises an alcohol, such as ethanol, in combination with an alkoxylated castor oil, such as CREMOPHOR® EL, or comprising a retinide, such as fenretinide, in an emulsion composed of a lipoid dispersed in an aqueous phase, a stabilizing amount of a non-ionic surfactant, optionally a solvent, and optionally an isotonic agent. In addition, a method of use in the treatment of hyperproliferative disorders, such as cancers is described.Type: ApplicationFiled: December 5, 2001Publication date: December 5, 2002Inventors: Shanker Gupta, Barry J. Maurer, C. Patrick Reynolds, B. Rao Vishnuvajjala